<SEC-DOCUMENT>0001193125-17-312214.txt : 20171018
<SEC-HEADER>0001193125-17-312214.hdr.sgml : 20171018
<ACCEPTANCE-DATETIME>20171018083102
ACCESSION NUMBER:		0001193125-17-312214
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20171018
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20171018
DATE AS OF CHANGE:		20171018

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		171141793

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d474823d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): October&nbsp;18, 2017 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;18, 2017, FibroGen, Inc. (Company) and its subsidiary,
FibroGen China Medical Technology Development Co., Ltd., announced that the China Food and Drug Administration has accepted the Company&#146;s submission of its New Drug Application (NDA) for registration of roxadustat
<FONT STYLE="white-space:nowrap">(FG-4592</FONT> or


<IMG SRC="g4748238k_1.jpg" ALT="LOGO">
), a novel oral investigational treatment for anemia in dialysis-dependent chronic kidney disease (CKD) and <FONT STYLE="white-space:nowrap">non-dialysis-dependent</FONT> CKD patients.&nbsp;Under the terms of
FibroGen&#146;s agreement with AstraZeneca AB, a collaboration partner of the Company, the NDA submission triggers a $15&nbsp;million milestone payment, payable to the Company by AstraZeneca. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top">Exhibits </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:23.50pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d474823dex991.htm">Press Release titled &#147;FibroGen Announces Acceptance by China FDA of Roxadustat New Drug Application (NDA) for Treatment of Anemia Associated with Dialysis and <FONT STYLE="white-space:nowrap">Non-Dialysis
</FONT> Chronic Kidney Disease (CKD)&#148; dated October&nbsp;18, 2017 </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>F<SMALL>IBROGEN</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: October&nbsp;18, 2017</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Counsel</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d474823dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g474823g1018072818489.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>NEWS RELEASE</B></TD></TR>
</TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FIBROGEN ANNOUNCES ACCEPTANCE BY CHINA FDA OF ROXADUSTAT NEW DRUG </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APPLICATION (NDA) FOR TREATMENT OF ANEMIA ASSOCIATED WITH DIALYSIS AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">NON-DIALYSIS</FONT> CHRONIC KIDNEY DISEASE (CKD) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Triggers Milestone Payment of $15 Million by AstraZeneca </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, Oct. 18, 2017 &#151; FibroGen, Inc. (NASDAQ:FGEN), a science-based biopharmaceutical company, and its subsidiary FibroGen China Medical
Technology Development Co., Ltd. (FibroGen China), today announced that the China Food and Drug Administration (CFDA) has accepted the company&#146;s recently submitted New Drug Application for registration of roxadustat <FONT
STYLE="white-space:nowrap">(FG-4592</FONT> or


<IMG SRC="g47482311_1.jpg" ALT="LOGO">
), a novel oral investigational treatment for anemia in dialysis-dependent CKD <FONT STYLE="white-space:nowrap">(DD-CKD)</FONT> and <FONT STYLE="white-space:nowrap">non-dialysis-dependent</FONT> CKD <FONT
STYLE="white-space:nowrap">(NDD-CKD)</FONT> patients. Under the terms of FibroGen&#146;s agreement with AstraZeneca, the NDA submission triggers a $15&nbsp;million milestone payment, payable to FibroGen by AstraZeneca. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;This is an important milestone for FibroGen and for roxadustat. We look forward to working with the CFDA on this important new drug registration
application process,&#148; said Thomas B. Neff, FibroGen&#146;s Chief Executive Officer. &#147;In China, there is a significant need for a new therapeutic for patients with anemia associated with CKD, a serious and potentially life-threatening
condition.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are grateful for the opportunity to address a substantial unmet medical need for the treatment of anemia associated with CKD in
China, where the CKD dialysis population is growing rapidly and large segments of the CKD <FONT STYLE="white-space:nowrap">non-dialysis</FONT> population are not reached by current therapies,&#148; said Chris Chung, FibroGen&#146;s Vice President of
China Operations. &#147;If approved, roxadustat will be the first <FONT STYLE="white-space:nowrap">HIF-PHI</FONT> available worldwide, with China as the first approval country for this
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> drug.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The New Drug Application for roxadustat is
based on the results of FibroGen&#146;s two Phase 3 multi-center, randomized, controlled studies conducted in China, one study in CKD dialysis comparing roxadustat against a branded epoetin alfa, and one study in CKD
<FONT STYLE="white-space:nowrap">non-dialysis</FONT> comparing roxadustat against placebo. Both of the Phase 3 studies met their primary efficacy endpoints with no new or unexpected safety signals identified. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Anemia Associated with CKD in China </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Anemia
commonly develops in association with chronic kidney disease and is linked to significant morbidity and mortality in both the dialysis and <FONT STYLE="white-space:nowrap">non-dialysis</FONT> populations. CKD affects an estimated 119.5&nbsp;million
patients in China. Although CKD may occur at any age, it is more common in aging populations, and its prevalence is increasing. CKD can be both a cause and a consequence of cardiovascular disease and is a critical healthcare issue. With the
exception of kidney transplantation, there is no treatment available that is curative, or has the ability to stop kidney deterioration.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The dialysis
population in China, which exceeds 400,000 patients, has been growing at a double-digit rate. The number of patients that require anemia therapy in China and other emerging markets is expected to increase steadily, as the CKD population continues to
grow and the number of hemodialysis and peritoneal dialysis patients increases. There is a significant opportunity for roxadustat to treat patients on dialysis (hemodialysis and peritoneal dialysis) and not on dialysis, as well as to address need in
the large number of patients whose anemia remains undertreated or untreated in China. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Roxadustat </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Roxadustat (FG-4592) is a first-in-class, orally administered small molecule in global Phase 3 clinical development worldwide as a therapy for anemia
associated with chronic kidney disease (CKD) with the potential to offer a safer, more effective, more convenient, and more accessible treatment than the current therapies available for anemia in CKD, such as injectable erythropoiesis stimulating
agents (ESAs). Roxadustat promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin. Administration of roxadustat has been shown to induce coordinated erythropoiesis &#150; increasing red
blood cell count while maintaining plasma erythropoietin levels within or near normal physiologic range in multiple subpopulations of CKD patients &#150; including in the presence of inflammation and without a need for supplemental intravenous
iron.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, along with collaboration partners Astellas Pharma Inc. and AstraZeneca AB, has designed a Phase 3 program to support regulatory approval
of roxadustat for both <FONT STYLE="white-space:nowrap">NDD-CKD</FONT> and <FONT STYLE="white-space:nowrap">DD-CKD</FONT> patients worldwide. To date, this is the largest Phase 3 clinical program in anemia, enrolling more than 10,000 subjects
worldwide. FibroGen anticipates filing a U.S. New Drug Application (NDA) for roxadustat for the treatment of anemia associated with CKD in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen
and its partner AstraZeneca are collaborating on the development and commercialization of roxadustat in the U.S., China, and other markets.&nbsp;In China, FibroGen China is conducting all clinical trials and will hold all roxadustat regulatory
licenses and permits to be issued by China regulatory authorities. After market approval, FibroGen China will manage manufacturing and medical affairs and AstraZeneca will manage launch and commercialization activities in China. FibroGen and
Astellas are collaborating for the development and commercialization of roxadustat in Europe, Japan, the Commonwealth of Independent States, the Middle East, and South Africa. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the next stage of its development program, roxadustat is entering a Phase 2/3 clinical trial in China and a Phase 3 clinical trial in the U.S. for the
treatment of anemia in patients with myelodysplastic syndromes (MDS). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For information about roxadustat studies currently recruiting patients, please
visit clinicaltrials.gov at: <FONT STYLE="white-space:nowrap">https://clinicaltrials.gov/ct2/results?term=FG-4592&amp;Search=Search</FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
FibroGen, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco, CA with subsidiary offices in Beijing and Shanghai, PRC, is a leading science-based
biopharmaceutical company discovering and developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible
factor (HIF) and connective tissue growth factor (CTGF) biology and clinical development to advance innovative medicines for the treatment of anemia, and fibrotic disease and cancer. Roxadustat, the company&#146;s most advanced product candidate, is
an oral small molecule inhibitor of HIF prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD) with the exception of China, where a new drug application is currently under
review by the CFDA for </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval. Roxadustat is also entering Phase 3 development for anemia in myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, a fully-human monoclonal antibody, that inhibits the activity
of CTGF, is in Phase&nbsp;2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), pancreatic cancer, and Duchenne muscular dystrophy (DMD). FibroGen is also developing a biosynthetic cornea in China. For more information,
please visit www.fibrogen.com. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development of the
company&#146;s product candidate roxadustat in China, the potential safety and efficacy profile of roxadustat and its potential to treat patients, including in anemia associated with myelodysplastic syndromes, and our clinical plans, including
timing for planned initiation of clinical trials in China and the U.S. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and
typically are identified by use of terms such as &#147;may,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148;
&#147;potential,&#148; &#147;continue&#148; and similar words, although some forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and
uncertainties related to the continued progress and timing of our various programs, including the enrollment and results from ongoing and potential future clinical trials for pamrevlumab, and other matters that are described in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2016, and our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2017 and June&nbsp;30, 2017,
respectively, filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this
release, and we undertake no obligation to update any forward-looking statement in this press release, except as required by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # #
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">kbergman@fibrogen.com </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g47482311_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g47482311_1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ #P ] P$1  (1 0,1 ?_$ %L   ,! 0
M      <("04& 0$                     $  !!0$! 0 " P         &
M P0%!P@" 0D3%  5%Q$!                     /_:  P# 0 "$0,1 #\
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M?\6 EPZ)>RWF>Z.2BHWV-"8A9/N/8LO5WJBT@]6?OG()5EVW9BH98O#R+/\
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7N(QZ-N8CR.ZD>H-XA'>\\^^>..P__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g4748238k_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g4748238k_1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ #@ X P$1  (1 0,1 ?_$ %T   ,! 0
M      4'" D& 0$                     $  !! ,!  (" P         &
M P0%!P$"" D4%1(3 !<8$0$                     _]H # ,!  (1 Q$
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4"L>]D?N'S6/2E<+.'JB26/T!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g474823g1018072818489.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g474823g1018072818489.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  E (P# 2(  A$! Q$!_\0
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M_A/J=C)87"W<CG9"8R';E>W6A-6%)&G\-O#NGIX:AU*2"*:YNBQ+N@;: Q
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K** 84&BBF" 8]*6BB@!#TS1113%<6D/7-%%2,!TI:**.@!3<T452&C__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
